STAT August 7, 2024
LONDON — An underwhelming earnings report and ongoing questions about increasing competition in the booming obesity medicine field sent Novo Nordisk’s shares down early Wednesday, as the company sought to project its ability to reach more patients by increasing the supplies of its medicines.
Novo shares were down about 5% after the company lowered its operating profit guidance to 20% to 28%,...